JP6475225B2 - 治療上の使用のための抗ｂａｇ３抗体 - Google Patents

治療上の使用のための抗ｂａｇ３抗体 Download PDF

Info

Publication number
JP6475225B2
JP6475225B2 JP2016503735A JP2016503735A JP6475225B2 JP 6475225 B2 JP6475225 B2 JP 6475225B2 JP 2016503735 A JP2016503735 A JP 2016503735A JP 2016503735 A JP2016503735 A JP 2016503735A JP 6475225 B2 JP6475225 B2 JP 6475225B2
Authority
JP
Japan
Prior art keywords
bag3
antibody
pharmaceutical composition
composition according
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016503735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516078A5 (https=
JP2016516078A (ja
Inventor
カテリーナ タルコ マリア
カテリーナ タルコ マリア
Original Assignee
ビオウニヴェルサ ソシエタ ア レスポンサビリタ リミタータ
ビオウニヴェルサ ソシエタ ア レスポンサビリタ リミタータ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビオウニヴェルサ ソシエタ ア レスポンサビリタ リミタータ, ビオウニヴェルサ ソシエタ ア レスポンサビリタ リミタータ filed Critical ビオウニヴェルサ ソシエタ ア レスポンサビリタ リミタータ
Publication of JP2016516078A publication Critical patent/JP2016516078A/ja
Publication of JP2016516078A5 publication Critical patent/JP2016516078A5/ja
Application granted granted Critical
Publication of JP6475225B2 publication Critical patent/JP6475225B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Multiple-Way Valves (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016503735A 2013-03-18 2014-03-04 治療上の使用のための抗ｂａｇ３抗体 Active JP6475225B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2013A000403 2013-03-18
IT000403A ITMI20130403A1 (it) 2013-03-18 2013-03-18 Anticorpi anti-bag3 per uso terapeutico
PCT/IB2014/059416 WO2014147503A2 (en) 2013-03-18 2014-03-04 Anti-bag3 antibodies for therapeutic use

Publications (3)

Publication Number Publication Date
JP2016516078A JP2016516078A (ja) 2016-06-02
JP2016516078A5 JP2016516078A5 (https=) 2017-03-23
JP6475225B2 true JP6475225B2 (ja) 2019-02-27

Family

ID=48227407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503735A Active JP6475225B2 (ja) 2013-03-18 2014-03-04 治療上の使用のための抗ｂａｇ３抗体

Country Status (9)

Country Link
US (2) US20150329622A1 (https=)
EP (1) EP2976104B1 (https=)
JP (1) JP6475225B2 (https=)
KR (1) KR20150129649A (https=)
CN (1) CN104902927A (https=)
CA (1) CA2895472C (https=)
ES (2) ES2721935T3 (https=)
IT (1) ITMI20130403A1 (https=)
WO (1) WO2014147503A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131351A1 (it) 2013-08-07 2015-02-08 Biouniversa Srl Molecole leganti il recettore di bag3 per uso terapeutico.
ITUB20155097A1 (it) * 2015-11-05 2017-05-05 Biouniversa Srl Anticorpi umanizzati anti-BAG3
CN105769900A (zh) * 2016-03-22 2016-07-20 山西大学 Bag3基因在制备抗膀胱癌药物中的应用
IT201600111877A1 (it) * 2016-11-07 2018-05-07 Biouniversa Srl Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
CN114533877B (zh) * 2022-03-09 2023-07-04 上海交通大学医学院附属第九人民医院 Bag3抑制剂在制备治疗瘢痕产品中的用途
WO2026074330A1 (en) 2024-10-01 2026-04-09 Fibrosys S.R.L. Antibodies and diagnostic methods for detecting bag3 protein in clinical samples

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU774355B2 (en) * 1998-09-09 2004-06-24 Burnham Institute, The Novel bag proteins and nucleic acid molecules encoding them
EP1323733A1 (en) * 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
WO2009014759A2 (en) * 2007-07-25 2009-01-29 The Trustess Of Columbia University In The City Of New York Methods of inhibiting vzv replication and related compositions
IT1397083B1 (it) * 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
EP2676966A1 (en) * 2012-06-19 2013-12-25 Biouniversa S.r.l. BAG3 as biochemical serum and tissue marker

Also Published As

Publication number Publication date
WO2014147503A3 (en) 2014-12-04
US20150329622A1 (en) 2015-11-19
ITMI20130403A1 (it) 2014-09-19
CN104902927A (zh) 2015-09-09
JP2016516078A (ja) 2016-06-02
ES2650942T3 (es) 2018-01-23
WO2014147503A2 (en) 2014-09-25
ES2721935T3 (es) 2019-08-06
US20190010221A1 (en) 2019-01-10
CA2895472A1 (en) 2014-09-25
KR20150129649A (ko) 2015-11-20
EP2976104A2 (en) 2016-01-27
EP2976104B1 (en) 2019-01-30
US11117957B2 (en) 2021-09-14
CA2895472C (en) 2022-07-05

Similar Documents

Publication Publication Date Title
JP7464764B2 (ja) 抗ｒｏｒ１抗体とその作製及び使用方法
JP7143452B2 (ja) ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用
JP6475225B2 (ja) 治療上の使用のための抗ｂａｇ３抗体
AU2022252753B2 (en) ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF
US20220162331A1 (en) Anti-cd73 monoclonal antibody and application thereof
ES2784131T3 (es) Polipéptidos de unión beta del receptor PDGF
JP2022104941A (ja) ヒト化抗ｃｄ７３抗体
KR102166083B1 (ko) 브라디키닌 b1 수용체 리간드에 대한 항체
WO2020019135A1 (zh) 一种抗cd47抗体及其应用
JP2022528061A (ja) 抗クローディン１８．２抗体及びその用途
ES2724364T3 (es) Procedimiento de tratamiento de fibrosis pulmonar idiopática
JP2020188765A (ja) Ｌｏｘ１特異的結合タンパク質及びその使用
JP7517702B2 (ja) Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体
CN106164094A (zh) 双特异性抗原结合多肽
AU2017207082A1 (en) Anti-Myl9 antibody
CN116323657B (zh) 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
CN106029092B (zh) 能够溶解带有膜锚定型免疫球蛋白a的b淋巴球与降低免疫球蛋白a生产的抗人类膜锚定型免疫球蛋白a抗体
US20230065416A1 (en) Clathrin-chimetic antibody receptor constructs for immune cell activation therapy in vivo
BR112018072140B1 (pt) Anticorpos anti-basigin humanizados, sequência de ácidos nucleicos, composição e uso dos mesmos
HK1206754B (en) Antibodies to bradykinin b1 receptor ligands

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190131

R150 Certificate of patent or registration of utility model

Ref document number: 6475225

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250